Cargando…
Sodium-Glucose Cotransporter (SGLT2) inhibitors: A new Era in renovascular protection
Diabetic kidney disease (diabetic nephropathy), one of the most serious renovascular diabetic complication represents the leading cause of chronic kidney disease worldwide and is characterized clinically by impaired renal functional indices, hypertension, systemic and renal hemodynamic changes and p...
Autor principal: | Berbari, Adel E. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7803021/ https://www.ncbi.nlm.nih.gov/pubmed/33447779 http://dx.doi.org/10.1016/j.ijchy.2020.100058 |
Ejemplares similares
-
A Call for a New Paradigm for Diabetes Care in the Era of Sodium–Glucose Cotransporter 2 Inhibitors (SGLT2i)
por: Kim, Sun H., et al.
Publicado: (2020) -
Sodium-glucose cotransporter 2 (SGLT-2) inhibition and kidney protection: Does improvement in kidney hypoxia play a role?
por: Burnier, Michel
Publicado: (2021) -
Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors: A Clinician’s Guide
por: Simes, Bryce C, et al.
Publicado: (2019) -
Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors: Benefits Versus Risk
por: Jasleen, Bains, et al.
Publicado: (2023) -
Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors: Harms or Unexpected Benefits?
por: Andreea, Munteanu Madalina, et al.
Publicado: (2023)